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ABSTRACT		
Background:	 Endoscopic	 stenting	 proved	 to	 be	 a	 safe	 alternative	 to	 surgery	 for	
malignant	intra-abdominal	gastrointestinal	obstruction.	Although	high	technical	success	
rates	are	reported,	some	patients	do	not	experience	symptoms	relief.	Aim:	To	analyse	
factors	 predicting	 effectiveness	 of	 stent	 placement	 in	 patients	 with	 gastrointestinal	
obstruction.	
	
Methods:	Retrospective	study	including	160	patients	submitted	to	palliative	stenting	for	
intra-abdominal	 obstruction	 in	 a	 tertiary	 centre,	 from	December	 2012	 to	 July	 2017.	
Technical	and	clinical	success,	stent	dysfunction	and	adverse	events	were	analysed.	
	
Results:	Technical	 success	was	of	 98%.	Early	 clinical	 success	was	of	 69%	and	81%	 in	
upper	and	lower	gastrointestinal	obstructions,	respectively	(p=0.107).	In	the	upper	tract,	
obstruction	caused	by	carcinomatosis	was	the	only	independent	factor	predicting	early	
and	 late	 clinical	 failure	 (OR	 9.7,	 95%CI	 2.4-38.4,	 p=0.001;	 OR	 7.6,	 95%CI	 1.8-31.9,	
p=0.006,	 respectively)	 and	 absence	 of	 late	 clinical	 benefit	 (OR	 9.2,	 95%CI	 1.8-47.0,	
p=0.008).	In	the	colon,	ECOG	score≥3	was	an	independent	factor	for	early	clinical	failure	
(OR	29.8,	95%CI	1.9-464.9,	p=0.002)	and	obstruction	caused	by	carcinomatosis	was	an	
independent	 factor	 for	 late	 clinical	 failure	 (OR	 14.4,	 95%CI	 1.7-119.6,	 p=0.013)	 and	
absence	of	late	clinical	benefit	(OR	8.3,	95%CI	1.2-57.5,	p=0.035).	Perforation	occurred	
in	 4	 patients	 (2.5%)	 and	 stent	 dysfunction	 occurred	 in	 15%	 of	 patients	 (4%	 stent	
migration;	9%	reestenosis).	Carcinomatosis	was	a	risk	factor	for	perforation	(p=0.039)	
and	migration	was	higher	with	shorter	6	cm	stents	(p=0.044).	
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Conclusion:	 Stents	 are	 effective	 and	 safe	 for	 palliating	 intra-abdominal	 obstruction.	
Carcinomatosis	predicts	an	unfavourable	clinical	outcome.	Palliative	stenting	should	be	
carefully	weighed	in	these	patients.	
	
Keywords:	stents;	intestinal	obstruction;	carcinoma;	stomach	neoplasms;	colorectal	
neoplasms	 	
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Introduction		
Gastrointestinal	 (GI)	 tumors	 are	 among	 the	 most	 common	 malignant	 diseases	
worldwide.	In	fact,	colorectal	cancer	is	the	second	most	commonly	diagnosed	cancer	in	
females	and	third	in	males.	Similarly,	gastric	cancer	is	within	the	five	most	commonly	
diagnosed	 cancers	 in	 both	 gender.[1]	 These	 frequent	malignancies	 often	 present	 at		
advanced	unresectable	stages	requiring	palliative	care.[2]	[3]	
Irrespective	 of	 GI	 segment	 affected,	 intra-abdominal	 malignancies	 can	 result	 in	
intestinal	 obstruction	with	 dreadful	 clinical	 conditions	 that	 lead	 to	 severe	 symptom,	
impaired	quality	of	life	and,	in	more	advanced	stages,	patient’s	death.[4,5]	In	most	of	
these	 cases,	 curative	 treatment	 is	 no	 longer	 possible	 and	 the	 focus	 is	 on	 symptom	
control	 and	 palliation.	 Therefore,	 minimally	 invasive	 methods	 are	 preferred	 in	 this	
setting.			
In	 the	 past,	 the	 standard	 treatment	 for	 malignant	 gastric	 and	 duodenal	 outlet	
obstruction	 was	 surgical	 gastrojejunostomy	 and	 for	 colorectal	 obstruction	 was	
colostomy.	However,	in	recent	years,	palliative	endoscopic	stenting	has	been	used	as	an	
alternative	to	surgery	to	manage	the	stenosis.	[6-9]		
Endoscopic	 stenting	 is	 suggested	 in	current	practice	as	a	 safe	and	minimally	 invasive	
method	 for	 re-establishing	 luminal	 continuity	 and	 relieving	 GI	 obstructive	
symptoms.[10]	Although	endoscopic	stenting	has	been	reported	to	have	a	high	technical	
success,	the	reported	clinical	success	is	not	as	high	and	some	patients	still	complain	of	
ongoing	symptoms	after	the	procedure.[11]		
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Accordingly,	our	aim	was	to	determine	the	overall	clinical	benefit	and	predictive	factors	
for	 unsuccessful	 clinical	 outcomes	 and	 adverse	 events	 of	 palliative	 GI	 stenting	 for	
malignant	 intra-abdominal	 obstruction,	 arguing	 in	 favor	 of	 a	 more	 individualized	
approach	to	these	patients.	
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Materials	and	Methods	
Study	design	and	selection	of	Patients	
We	 conducted	 a	 retrospective	 study	 of	 a	 consecutive	 series	 of	 patients	 undergoing	
either	gastroduodenal	or	colorectal	stent	placement	for	treatment	of	malignant	intra-
abdominal	 gastroduodenal	 or	 colonic	 obstruction	 in	 a	 tertiary-care	 medical	 centre	
(Instituto	Português	de	Oncologia	do	Porto	Francisco	Gentil,	E.P.E),	between	December	
2012	 and	 July	 2017.	 The	 study	 was	 approved	 by	 the	 Ethics	 Committee	 of	 Instituto	
Português	de	Oncologia	do	Porto	Francisco	Gentil,	E.P.E	
Patients	were	included	if	palliative	stent	placement	was	indicated	for	either	upper	or	
lower	GI	 tract	 obstruction	 and	 recommended	 in	 a	multidisciplinary	 decision	 (1);	 had	
clinically	 and	 imagiologically	 documented	 unresectable	 malignant	 cancers	 (2);	 with	
symptoms	 of	 obstruction	 of	 the	 stomach,	 duodenum	 or	 colon,	 such	 as	 vomiting,	
obstipation,	diarrhoea	or	abdominal	pain	(3).	
Patients	were	excluded	if	they	had	a	non-palliative	indication	for	stenting,	such	as	bridge	
to	surgery.	In	addition,	patients	without	follow-up	clinical	records	were	also	excluded.	
Stent	placement	
Two	 fully	 trained	 endoscopists	 with	 different	 levels	 of	 experience	 were	 involved:	
endoscopist	1	(RS),	with	more	than	10	years	of	stent	placement	experience	and	over	
500	intra-abdominal	stents	placed;	and	endoscopist	2	(PPN),	with	more	than	5	years	of	
stent	placement	experience	and	more	than	50	intra-abdominal	stents	placed.			
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Diameter	of	the	stents	varied	from	22	to	27	mm	and	length	varied	from	6,	9	or	12	cm	
(Boston	Wallstent ™	and	Cook	Evolution™	duodenal	or	colonic	Stents),	depending	on	
the	 patients’	 conditions	 and	 obstructive	 causes.	 All	 stents	 were	 deployed	 under	
endoscopic	and	fluoroscopic	guidance	and	patients	were	sedated	with	propofol.	
The	 stenting	 procedure	 was	 always	 performed	 with	 a	 forward	 viewing	 therapeutic	
endoscope	(GIF	2TH	180;	Olympus	Medical	Systems,	Tokyo,	Japan)	or	colonoscope	(GIF	
165,	180	or	190	Olympus	Medical	Systems,	Tokyo,	Japan)	with	a	3.7mm	working	channel.	
A	catheter	with	a	guidewire	was	used	 to	allow	the	endoscope	to	come	closer	 to	 the	
stenosis	 site.	 Firstly,	 the	 endoscope	 came	 close	 to	 the	 stenosis	 site,	 after	 which	 a	
guidewire	was	passed	through	it.	Contrast	injected	through	the	catheter	was	used	for	
estimation	of	stenosis	length.	After	that,	the	appropriate	length	of	the	stent	was	chosen,	
considering	 the	 stent’s	 shortening	 after	 the	 extension.	 Finally,	 the	 stent	was	 placed	
under	endoscopic	and	fluoroscopic	guidance.	
Entry	point	and	Follow-up		
All	patients	were	followed-up	from	stent	placement	to	endpoint	or	death.	Stent	patency	
was	evaluated	in	every	patient	with	a	radiographic	examination	at	24	hours	(generally	
with	contrast	for	gastroduodenal	obstruction).	In	the	absence	of	any	complication,	every	
patient	started	a	liquid	diet	within	24	hours	after	the	procedure.			
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Definition	of	risk	factors	and	endpoints	
Clinical	 data	 was	 collected	 from	 electronical	 clinical	 records.	 The	 presence	 of	
carcinomatosis	was	proven	histologically;	cytologically	or	by	imaging	exams	such	as	MRI	
scan;	CT	scan	or	ultrasound.	
Our	 primary	 outcome	 was	 clinical	 success	 and	 benefit	 of	 stent	 placement.	 Other	
endpoints	were:		technical	success;	stent	dysfunction	and	adverse	events.	
Technical	success	was	defined	as	an	adequate	placement	of	the	self-expandable	metal	
stent	across	the	stenosis,	confirmed	by	a	combination	of	endoscopy	and	fluoroscopy.		
Early	and	late	clinical	success	were	defined	as	tolerance	for	food	intake,	regular	stool	
canalization	 and	 relief	 of	 obstructive	 symptoms,	 with	 no	 procedure-related	 adverse	
events	 and	 no	 subsequent	 intervention	 at	 7	 and	 30	 days	 (respectively)	 after	 the	
procedure	or	at	time	of	death	if	the	patient	died	before	evaluation.		
Late	clinical	benefit	was	considered	when	the	patient	was	alive	and	had	tolerance	for	
food	intake,	regular	stool	canalization	and	obstructive	symptom	relief	at	30	days,	the	
same	 as	 late	 clinical	 success	 but	 death	was	 not	 considered	 as	 a	 benefit	 (even	 if	 the	
patient	died	with	no	symptoms	of	obstruction),	since	these	patients	did	not	benefit	of	
the	stent	for	more	than	1	month.	
Stent	 dysfunction	 was	 considered	 when	 there	 was	 a	 recurrence	 of	 the	 obstructive	
symptoms	due	to	stent	migration,	restenosis	or	other	factors	impairing	stent	function.		
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Statistical	analysis	
Statistical	analysis	was	performed	using	IBM	SPSS	version	24.0	(IBM	Corp.,	Armonk,	N.Y.,	
USA).	 Categorical	 variables	 were	 analysed	 using	 Chi-square	 test	 or	 Fisher’s	 test	 and	
continuous	variables	were	expressed	as	mean	and	standard	deviation,	and	compared	
using	student	t	test.		
Logistic	regression	was	applied	to	analyse	factors	associated	independently	with	clinical	
success.	Odds	ratio	(OR)	and	95%	confidence	 intervals	 (CIs)	were	reported	for	failure	
and	not	for	success.	A	p-value	of	<	0.05	was	considered	statistically	significant.	Overall	
survival	and	symptom-free	survival	were	analysed	using	Kaplan-Meier	analysis.	
Overall	survival	was	calculated	from	the	time	of	stent	placement	until	the	time	of	death	
or	endpoint	of	this	study,	if	the	patient	remained	alive.	Censored	values	were	patients	
who	were	still	alive	at	the	end	of	the	study.	Symptom-free	survival	was	defined	as	the	
time	 from	 initial	 stent	 placement	 until	 the	 recurrence	 of	 clinical	 symptoms,	 stent	
dysfunction	 (obstruction,	 migration	 or	 perforation)	 or	 death.	 Censored	 values	 were	
patients	who	were	still	symptom-free	at	the	end	of	the	study.	
	
Results	
Patient’s	Characteristics		
One	hundred	and	sixty-five	intra-abdominal	stents	were	placed	during	the	study	period.	
Three	patients	were	excluded	because	they	had	a	stent	indication	for	bridge	to	surgery	
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(2%).	In	addition,	two	patients	who	didn’t	have	clinical	records	for	follow-up	after	the	
procedure	were	also	excluded	(1%).			
In	total,	160	patients	had	a	palliative	indication	for	stent	placement	and	were	considered	
for	analysis.	 The	baseline	characteristics	of	 these	patients	are	 shown	 in	Table	1.	The	
mean	 age	 was	 64	 ±	 14	 years	 and	 53%	 of	 patients	 were	 male.	 The	 ECOG	 (Eastern	
Cooperative	Oncology	Group)	 performance	 status	was	 ≥	 3	 in	 52	patients	 (33%).	 The	
primary	tumour	was	gastric	cancer	in	82	patients	(51%);	pancreatic	cancer	in	20	patients	
(13%);	colorectal	cancer	in	44	patients	(28%);	gynaecological	cancer	in	12	patients	(8%)	
and	 others	 (mesothelioma	 and	 unknown)	 in	 1%	 of	 patients.	 Uncovered	 stents	were	
placed	 in	 99%	 of	 the	 cases.	 One	 hundred	 patients	 (63%)	 had	 been	 submitted	 to	
treatment	before	stent	placement	(either	chemotherapy,	radiotherapy	and/or	surgery).		
	
Technical	success	
Technical	 success	was	 achieved	 in	 157	 patients	 (98%).	 Three	 patients	 only	 achieved	
successful	stent	placement	in	a	second	procedure	but	were	considered	to	have	technical	
success.	Technical	failure	occurred	in	3	cases	because	the	guidewire	was	unable	to	pass	
through	 the	 stenosis	 site	 (one	 in	 a	 gastroduodenal	 obstruction	 and	 2	 in	 colorectal	
obstructions).	 In	 all	 cases	 of	 technical	 failure,	 the	 obstruction	 was	 caused	 by	
carcinomatosis.	 The	 three	 patients	 without	 technical	 success	 were	 excluded	 from	
further	analysis.		
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Factors	predicting	early	and	late	clinical	success	
Overall,	 114	 (73%)	 patients	 reached	early	 clinical	 success:	 75	patients	with	 upper	GI	
obstruction	and	39	with	lower	GI	tract	obstruction	(69%,	OR	1.2,	95%CI	0.9-1.5	vs	81%,	
0.6	OR,	95%CI	0.3-1.2,	p=0.107,	respectively)	(Table	2).		
Carcinomatosis	and	previous	treatment	were	significantly	associated	with	a	worse	early	
clinical	outcome	(OR	1.9,	95%CI	1.4-2.5,	p<0.001	and	OR	1.3,	95%CI	1.0-1.7,	p=0.041,	
respectively).	(Table	2)			
In	 the	 subanalysis	 of	 the	 upper	 and	 lower	 GI	 tract	 obstruction	 (Table	 3),	 previous	
treatment	was	significantly	associated	with	a	worse	early	clinical	outcome	in	the	upper	
GI	tract	(OR	1.4,	95%CI	1.0-1.8,	p=0.046),	ECOG	performance	score	≥3	was	associated	
with	a	worse	early	clinical	outcome	in	the	lower	GI	tract	(OR	3.8,	95%CI	1.9-7.7,	p=0.001)	
and	carcinomatosis	was	associated	with	a	worse	early	clinical	outcome	in	both	the	upper	
and	lower	GI	tracts	(OR	1.7,	95%CI	1.2-2.3,	p=0.002	and	OR	2.4,	95%CI	1.2-4.7,	p=0.03,	
respectively).	In	addition,	obstruction	caused	by	carcinomatosis	was	related	to	a	worse	
early	 clinical	outcome	 in	both	 the	upper	and	 lower	GI	 tract	 (OR	4.9,	95%CI	1.8-12.9,	
p<0.001	and	OR	3.5,	95%CI,	1.2-10.4,	p=0.028,	respectively)	(Table	4).		
In	the	multivariate	analysis	of	factors	related	to	early	clinical	failure	(Table	5),	we	found	
that,	 in	 the	 upper	GI	 tract,	 carcinomatosis	 as	 the	 cause	 of	 obstruction	was	 the	 only	
independent	factor	for	early	clinical	failure	(OR	9.7,	95%CI	2.5-38.4,	p=0.001).	In	addition,	
the	 presence	 of	 carcinomatosis	 without	 it	 being	 the	 cause	 of	 obstruction	 showed	 a	
tendency	for	worse	early	clinical	outcome	(OR	2.8,	95%CI	1.0-7.9,	P=0.051).	In	the	lower	
GI	tract,	ECOG	performance	score	≥3	was	the	only	independent	factor	for	worse	early	
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clinical	outcome	(OR	29.8,	95%CI	1.9-464.9,	p=0.002)	and	carcinomatosis	as	the	cause	
of	obstruction	had	a	tendency	for	a	worse	outcome	(OR	8.2,	95%CI	0.8-89.0,	p=0.084).	
Late	clinical	success	was	achieved	in	83	(53%)	patients:	54	patients	with	upper	GI	tract	
obstruction	and	29	patients	with	lower	GI	tract	obstruction	(50%	OR	1.1,	95%CI	0.9-1.4	
vs	60%	OR	0.9,	95%CI	0.5-1.6,	p=0.209)	(Table	2).		
At	30	days,	54	(34%)	patients	had	died:	43	with	upper	GI	obstruction	and	9	with	lower	
GI	obstruction	 (39%	vs	19%,	p=0.008).	 Late	clinical	benefit	was	achieved	 in	67	 (43%)	
patients:	 26	 patients	 with	 lower	 GI	 obstruction	 and	 41	 patients	 with	 upper	 GI	
obstruction,	there	was	a	tendency	for	better	outcome	in	the	first	group	(57%	OR	0.6,	
95%CI	0.4-1	vs	38%	OR	1.2,	95%CI	0.9-1.7,	p=0.053).	
Carcinomatosis	was	associated	with	a	worse	late	clinical	success	and	a	worse	late	clinical	
benefit	(OR	1.7,	95%CI	1.2-2.3,	p=0.002	and	OR	1.9,	95%CI	1.3-2.7	p<0.001,	respectively)	
(Table	2).		
In	the	subanalysis	of	 late	clinical	success	and	 late	clinical	benefit,	carcinomatosis	was	
associated	with	a	worse	late	clinical	outcome	in	both	the	upper	and	lower	GI	tract	(OR	
1.5,	95%CI	1.0-2.1,	p=0.027	and	OR	2.2,	95%CI	1.0-4.7,	p=0.044,	respectively)	and	with	
a	worse	late	clinical	benefit	in	the	upper	GI	tract	(OR	1.7,	95%CI	1.1-2.5,	p=0.009)	(Table	
3).	In	the	lower	GI	tract,	there	was	a	tendency	for	worse	clinical	benefit	in	patients	with	
carcinomatosis	 (OR	 2.2,	 95%CI	 1.0-4.9,	 p=0.052).	 ECOG	 performance	 score≥3	 had	 a	
tendency	for	late	clinical	failure	in	this	segment	(OR	2.3,	95%CI	0.9-5.4).	(Table	3)	
Obstruction	caused	by	carcinomatosis,	in	both	the	upper	and	lower	GI	tract,	was	related	
to	a	worse	late	clinical	outcome	(OR	4.3,	95%CI	1.3-14.1,	p=0.008	and	OR	5.3	95%CI	1.2-
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10.4	 p=0.009,	 respectively)	 and	 worse	 late	 clinical	 benefit	 (OR	 4.2,	 95%CI	 1.0-17.6,	
p=0.025	 and	 OR	 0.7,	 95%CI	 0.5-1.0,	 p=0.033,	 respectively).	 Obstruction	 caused	 by	
colorectal	cancer	was	related	to	a	greater	late	clinical	outcome	(OR	2.7,	95%CI	0.5-1.0,	
p=0.027)	and	late	clinical	benefit	(OR	0.7,	95%CI	0.5-1.0,	p=0.006)	in	the	lower	GI	tract.	
(Table	4)	
Multivariate	analysis	showed	that	obstruction	caused	by	carcinomatosis	was	the	only	
independent	factor	for	late	clinical	failure	in	both	the	upper	and	lower	GI	tract	(OR	7.6,	
95%CI	1.8-31.9,	p=0.006	and	OR	14.4,	95%CI	1.7-119.6,	p=0.013,	respectively)	(Table	5)	
and	also	for	absence	of	late	clinical	benefit	in	both	the	upper	and	lower	GI	tract	(OR	29.8,	
95%CI	1.9-464.9,	p=0.002	and	OR	8.3,	95%CI	1.2-57.5,	p=0.035,	respectively).	In	addition,	
the	 presence	 of	 carcinomatosis	 without	 it	 being	 the	 cause	 of	 obstruction	 showed	 a	
tendency	to	absence	of	late	clinical	benefit	(OR	2.2,	95%CI	0.9-5.5,	p=0.076)	(	(Table	5).	
Both	overall	survival	(122	days,	95%	CI	83-161	vs.	243,	95%	CI	154-333;	p=0.02)	(Figure	
1)	and	symptom-free	survival	(66	days,	95%	CI	32-100	vs.	183,	95%	CI	83-282;	p=0.002)	
(Figure	 2)	were	 lower	 in	 patients	with	 carcinomatosis	 compared	 to	 patients	without	
carcinomatosis.	
Factors	predicting	stent	dysfunction	and	perforation		
Stent	dysfunction	and	perforation	are	described	 in	Table	6.	Perforation	occurred	 in	4	
procedures	(2.5%),	all	occurring	in	patients	with	carcinomatosis	(p=0.039).	One	patient	
had	an	obstruction	caused	by	a	recurrence	of	gastric	cancer	in	an	anastomosis	site	and	
the	other	three	had	obstruction	caused	by	extraluminal	compression	by	carcinomatosis	
(1	patient	in	the	jejunum;	1	patient	in	the	antrum	and	1	in	the	sigmoid	colon).	All	of	the	
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4	patients	had	been	submitted	to	previous	treatment	(p=0.111),	three	of	them	had	been	
submitted	to	chemotherapy	(p=0.454).		
Stent	 dysfunction	 occurred	 in	 21	 patients	 (13%),	 7	 patients	 (15%)	 who	 had	 been	
submitted	to	colorectal	stent	placement	and	14	(13%)	patients	who	had	been	submitted	
to	gastroduodenal	stent	placement	(p=0.731).		
Of	the	7	patients	who	had	stent	migration,	one	had	an	accidental	exit	of	the	rectal	stent	
and	did	not	have	an	indication	for	a	second	stent	placement	and	another	patient	was	
submitted	to	colostomy	because	of	failure	to	retrieve	the	stent	that	migrated	from	the	
sigmoid	colon.	The	other	5	patients	were	submitted	to	a	second	stent	placement,	four	
gastroduodenal	and	one	colorectal	 stents.	Migration	was	associated	with	short	6	cm	
stents	(9%	vs	2%	p=0.044).	
Of	the	14	patients	with	stent	reestenosis,	one	patient,	whose	cause	of	obstruction	was	
gastric	 cancer,	 did	 not	 need	 reintervention	 because	 of	 clinical	 deterioration.	 Two	
patients	 were	 submitted	 to	 colostomy;	 one	 patient’s	 cause	 of	 obstruction	 was	
carcinomatosis	 and	 the	 other’s	was	 colorectal	 cancer.	 The	 other	 11	 patients	 had	 to	
receive	a	second	stent,	9	gastroduodenal	and	2	colorectal	stents.	We	did	not	find	any	
risk	factors	for	stent	restenosis	even	though	there	seemed	to	be	a	tendency	for	higher	
rate	of	 reestenosis	 in	patients	younger	than	65	years	old	 (13%	vs	5%,	p=0.108),	with	
ECOG≥3	(14%	vs	7%,	p=0.160)	and	those	submitted	to	previous	treatment	(11%	vs	5%,	
p=0.176).	
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Discussion	
Intra-abdominal	malignant	GI	tumors	may	lead	to	obstruction,	with	severe	symptoms	
that	greatly	affect	quality	of	life,	irrespective	of	GI	tract	segment	affected.	Moreover,	it	
can	compromise	additional	treatments	such	as	systemic	chemotherapy,	radiotherapy	or	
surgery.		Palliative	stenting	has	been	proven	to	be	a	safe	alternative	to	surgery,	but	not	
all	patients	benefit	of	this	treatment.[11]		
In	the	present	study,	we	aimed	to	understand	which	factors	were	implicated	in	patient’s	
clinical	outcome.	To	our	knowledge,	this	is	the	first	study	to	analyse	factors	predicting	
outcomes	 of	 palliative	 stenting	 in	 all	 causes	 of	 intra-abdominal	 GI	 obstruction,	
regardless	of	the	location	or	cause	of	obstruction.			
Technical	success	rate	was	98%	(similar	for	upper	and	lower	GI	segment)	and	in	line	with	
that	 of	 previous	 studies	 [7,8,12-18].	 Importantly,	 with	 the	 exception	 of	 obstruction	
caused	by	carcinomatosis,	stent	placement	was	always	possible.	Perforation	is	a	major	
adverse	 event	 that	 has	 to	be	 considered	when	pondering	 stent	 placement.	 Previous	
studies	have	shown	iatrogenic	perforation	rates	of	0	to	5%[11,13,18-23].	In	our	study	
population,	perforation	was	a	 rare	event,	occurring	 in	4	 (2.5%)	of	our	patients.	 In	all	
patients	carcinomatosis	was	present,	being	a	predictive	 factor	 for	 this	adverse	event	
(p=0.039).	Three	of	the	4	patients	had	been	submitted	to	chemotherapy	(p=0.454),	a	
factor	that	has	been	considered	to	be	related	to	this	adverse	event[24,25].	Additionally,	
all	 the	4	perforation	cases	occurred	 in	patients	with	previous	 treatments,	 suggesting	
that	this	may	be	a	risk	factor	for	this	complication.	In	our	study	this	association	was	not	
significant	because	the	study	was	underpowered	for	detecting	this	association	since	we	
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had	 very	 few	perforation	 cases.	 Therefore,	 in	 experienced	hands,	 it	 looks	 that	 intra-
abdominal	stent	placement	is	a	very	safe	and	feasible	procedure.	
Early	clinical	success	was	81%	in	lower	GI	tract	obstructions	and	69%	in	upper	GI	tract	
obstructions.	 When	 looking	 at	 the	 rates	 of	 early	 clinical	 success	 in	 each	 cause	 of	
obstruction	(Table	4),	they	are	similar	to	previous	studies.	In	fact,	pancreatic	cancer	had	
a	high	early	clinical	success	rate	(83%)	which	is	in	accordance	with	published	literature	
reporting	 early	 clinical	 success	 rates	 of	 83-88%	 [26,27].	 The	 same	 applies	 to	 gastric	
cancer	with	76%	of	patients	reaching	early	clinical	success,	also	comparable	to	a	recent	
study	by	Park	et	al,	which	compared	the	outcome	of	stenting	and	surgery	in	obstructions	
caused	by	gastric	cancer,	reporting	a	clinical	success	of	77%[28].	Colorectal	cancer	also	
had	a	high	rate	of	early	clinical	success	(87%)	similar	to	previous	data,	which	reported	
rates	of	85-100%	[23,29,30].	
On	 the	other	 hand,	when	 the	 cause	of	 obstruction	was	 recurrence	of	 stenosis	 in	 an	
anastomosis	site,	patients	had	a	clinical	success	rate	of	71%,	comparable	to	reported	
early	clinical	success	rate	of	70%	in	a	study	by	Cho	et	al.[31].	In	spite	of	this,	Park	MS	et	
al[32]	have	reported	higher	success	rates	(more	than	90%	in	different	types	of	gastric	
reconstruction)	in	a	large	series	report	of	196	patients,	which	differs	from	our	results	
probably	because	of	the	characteristics	of	the	baseline	population.		
We	had	few	cases	of	obstruction	caused	by	gynecological	cancer,	hepatic	metastasis	and	
adenopathies,	but	we	found	a	high	early	success	rate	in	the	first	two	groups	as	all	the	
patients	reached	symptom	relief	and	a	low	clinical	success	rate	in	the	second	(25%).	The	
two	last	groups	are	seldom	reported	in	literature.	
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Few	 studies	 have	 reported	 late	 clinical	 outcome	 at	 a	 specific	 follow-up	 time	 and	
therefore	there	is	no	consensual	definition	of	this	variable.		
We	defined	two	different	variables	to	reflect	two	different	late	outcomes:	late	clinical	
success	and	late	clinical	benefit.	 	The	first	variable	considered	that	patients	who	died	
before	30	days	but	were	free	of	obstructive	symptoms	at	time	of	death	reached	clinical	
success.	The	second	variable	considered	death	as	a	negative	outcome	because,	at	30	
days	 follow-up,	 only	 patients	 who	 were	 alive	 and	 without	 obstructive	 symptoms	
benefited	 from	 the	 stenting	 procedure.	 	 To	 our	 knowledge,	 this	 is	 the	 first	 study	 of	
endoscopic	 stenting	 that	 considers	 both	 of	 these	 important	 late	 clinical	 outcomes	
simultaneously.		
Patients	with	upper	GI	tract	obstruction	tended	to	have	an	earlier	death	compared	to	
patients	with	 lower	GI	 tract	obstruction	which	reflected	 in	a	tendency	for	worse	 late	
clinical	benefit	(p=0.053)	but	not	for	worse	late	clinical	success	(p=0.209).	This	difference	
shows	 that	 there	was	 a	 group	 of	 patients	with	 upper	GI	 tract	 obstruction	who	 died	
before	the	30	days	follow	up	that	were	symptom-free	at	the	time	of	death.	Even	though	
these	patients	improved	after	the	procedure,	they	died	soon	after	it	and	from	a	practical	
and	economical	point	of	view	it	is	arguable	if	stents	should	have	been	placed	in	these	
subjects.	
On	the	other	hand,	obstruction	caused	by	colorectal	cancer	was	related	to	a	better	late	
clinical	outcome	as	well	as	a	better	 late	clinical	benefit.	These	 findings	 reflect	better	
prognosis	and	longer	survival	of	patients	with	colorectal	cancer.	Similarly,	Keswani	et	al	
found	that	stent	palliation	of	obstruction	caused	colorectal	cancer	had	a	better	clinical	
		
18	
outcome	 than	 extracolonic	 obstructive	 causes.[33]	 Furthermore,	 Moon	 et	 al	 also	
compared	 these	 two	 groups	 and	 although	 they	 did	 not	 find	 significant	 early	 clinical	
differences,	they	found	that	patients	who	underwent	palliation	for	obstructions	caused	
by	 colorectal	 cancer	 had	 a	 higher	 overall	 and	 stent-patency	 survival,	 compared	 to	
patients	with	extracolonic	malignancies.[29]		
Previous	 data	 has	 reported	 the	 presence	 of	 carcinomatosis	 as	 a	 predictor	 of	 worse	
clinical	 outcome	 in	 both	 gastroduodenal	 and	 colorectal	 obstruction.	 Rademacher	 et	
al[34]	 compared	 clinical	 success	 of	 gastroduodenal	 obstruction	 patients	 with	 and	
without	carcinomatosis	and	found	that	the	first	group	had	a	lower	rate	of	clinical	success	
(63%,	p=0.036).	 In	a	recent	study,	Faraz	et	al[19]	showed	that	carcinomatosis	was	an	
independent	 factor	 for	 worse	 clinical	 outcome	 in	 patients	 submitted	 to	 colorectal	
stenting	and	Lee	et	al	[17]	recognized	carcinomatosis	as	an	independent	factor	for	lower	
obstruction	 symptom-free	 survival.	 Furthermore,	 Shin	 et	 al[13],	 in	 a	 multivariable	
analysis,	 found	 that	 carcinomatosis	 was	 an	 independent	 factor	 for	 worse	 clinical	
outcome	in	gastroduodenal	stenting	(p<0.001).	In	spite	of	these	results,	Mendelson	et	
al[18]	 didn’t	 find	 differences	 in	 clinical	 outcomes	 of	 patients	 with	 or	 without	
carcinomatosis	 in	 gastroduodenal	 stenting.	 However,	 in	 this	 study,	 patients	 with	
carcinomatosis	 weren’t	 considered	 for	 stent	 placement	 if	 they	 had	 more	 than	 one	
obstruction	site	or	if	their	lesions	were	thought	not	to	be	amenable	for	stent	placement,	
which	wasn’t	the	case	in	our	study	population,	since	these	factors	are	not	always	easy	
to	determine.	
In	accordance	with	these	studies,	we	found	that	the	presence	of	carcinomatosis	was	a	
		
19	
related,	in	the	univariate	analysis	of	upper	and	lower	GI	tract	obstruction,	to	both	early	
and	late	clinical	failure	as	well	as	lower	rates	of	late	clinical	benefit.	Furthermore,	we	
found	that	overall	survival	and	especially	symptom-free	survival	seemed	to	be	lower	in	
patients	who	had	carcinomatosis,	reflecting	a	more	advanced	stage	of	malignancy	and	
poor	 symptom	 relief,	 respectively.	 These	 results	 can	 be	 explained	 by	 the	 fact	 that	
carcinomatosis	 is	 associated	 with	 multiple	 obstruction	 sites	 and	 decreased	 bowel	
movements,	which	have	a	negative	influence	in	clinical	improvement.		
In	spite	of	this,	we	found	that,	more	important	than	the	sole	presence	of	carcinomatosis	
were	the	cases	when	carcinomatosis	itself	was	the	cause	of	obstruction.	In	fact,	to	our	
knowledge	this	is	the	first	study	analysing	the	outcome	of	palliative	stenting	in	patients	
with	carcinomatosis	as	the	cause	of	obstruction.	Our	results	showed	that	obstruction	
caused	 by	 carcinomatosis	was	 the	 only	 independent	 factor	 of	 early	 and	 late	 clinical	
failure	and	absence	of	clinical	benefit	in	the	upper	GI	tract	and	late	clinical	failure	and	
absence	of	clinical	benefit	 in	 the	 lower	GI	 tract.	Although	 it	was	not	an	 independent	
factor	for	early	clinical	failure	in	lower	GI	obstruction,	patients	showed	a	tendency	for	
worse	outcome.	 In	 fact,	patients	with	obstruction	caused	by	carcinomatosis	had	 low	
early	clinical	success	rates	of	31%	and	56%	in	the	upper	and	lower	GI	tract,	respectively.	
Furthermore,	the	presence	of	carcinomatosis	without	it	being	the	cause	of	obstruction	
showed	a	tendency	 for	a	worse	early	clinical	outcome	and	 late	clinical	benefit	 in	 the	
upper	GI	tract.		
Higher	 ECOG	 performance	 scores	 were	 also	 an	 independent	 factor	 for	 early	 clinical	
failure	in	the	lower	GI	tract.	This	could	be	explained	by	the	fact	that	patients	with	poorer	
performance	status	are	confined	to	a	bed	or	chair	for	most	of	the	waking	hours.	Bowel	
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movement	 is	 improved	 by	 low	 intensity	 exercise,	which	 is	 impaired	 in	 this	 group	 of	
patients.	This	impairment	justifies	their	poor	rates	of	stent	placement’s	clinical	success,	
in	spite	of	being	technically	successful.	[35]	This	variable	also	had	a	tendency	for	a	worse	
late	clinical	success	but	not	for	worse	late	clinical	benefit,	which	may	be	explained	by	
the	fact	that	the	patients	with	lower	ECOG	performance	scores	who	died	before	the	30	
days	follow-up	were	symptom-free.	Therefore,	although	performance	score	influenced	
obstructive	symptoms	within	the	first	month,	it	did	not	reflect	on	patient’s	survival	and	
benefit	at	30	days. 
Literature	 reports	 migration	 and	 restenosis	 rates	 of	 2%-9%	 and	 6%-31%	
respectively[13,14,20,22,36],	which	is	in	agreement	with	migration	and	restenosis	rates	
of	4%	an	9%	 in	our	 study.	We	 found	stent	migration	 to	be	more	 frequent	 in	 shorter	
stenosis	sites	(6cm).	It	has	been	described	in	previous	literature	that	migration	tends	to	
occur	with	stents	too	narrow	in	diameter	and/or	too	short	 in	 length	for	the	stricture	
they	are	placed	in[37].	Although	covered	stents	have	been	associated	with	higher	rates	
of	migration[38,39],	we	didn’t	find	this	in	our	study	probably	because	only	a	minority	of	
the	patients	was	submitted	to	covered	stent	placement	(n=2,	1.3%).	 
This	 was	 a	 nonrandomized,	 retrospective,	 single	 centre	 study,	 with	 its	 inherent	
disadvantages	 and	 limitations.	 Due	 to	 this	 study	 design,	 more	 than	 one	 physician	
performed	ECOG	scores	and	we	cannot	rule	out	interobserver	bias,	which	could	explain	
why	this	was	not	a	risk	factor	for	patients	with	upper	GI	tract	obstruction,	in	contrast	to	
the	lower	GI	tract.	In	fact,	although	we	did	not	find	this	in	our	study,	low	performance	
scores	have	been	associated	with	clinical	success	of	gastroduodenal	stenting	in	previous	
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articles[13,16,40].	In	addition,	we	were	unable	to	clearly	access	the	presence	and	level	
of	 ascites	 in	 all	 patients,	 which	 could	 have	 been	 a	 factor	 that	 would	 influence	 the	
multivariate	analysis	as	 it	was	considered	a	 risk	 factor	 in	other	studies[15,18,40].	So,	
future	 prospective	 studies	 analysing	 these	 variables	 would	 be	 of	 great	 interest.	
Furthermore,	 given	 that	 our	 stent	 dysfunction	 and	 perforation	 rates	 were	 low,	 our	
analysis	of	predictive	factors	isn’t	as	strong	as	it	would	be	if	we	had	a	bigger	group	of	
patients	with	these	complications.	On	the	other	hand,	this	study	had	some	advantages	
since	a	large	number	of	patients	and	a	long	follow	up	period	were	considered,	which	
enhances	our	understanding	of	GI	stenting	for	obstruction	caused	by	intra-abdominal	
malignancies.		
When	looking	at	specific	scenarios,	we	can	see	that	patients	with	obstruction	caused	by	
carcinomatosis	had	a	low	rate	of	clinical	success,	independently	of	the	location	of	the	
obstruction	(gastroduodenal	or	colorectal).	Only	22%	of	patients	with	lower	GI	tract	and	
13%	of	patients	with	gastroduodenal	obstruction	were	alive	at	30	days	and	were	free	of	
obstructive	symptoms,	respectively.	This	is	a	dreadful	scenario.	Stent	placement	is	an	
expensive	treatment	that	might	not	be	cost-effective	in	this	specific	setting.	In	addition,	
3	of	the	patients	in	this	group	suffered	perforation	related	to	the	procedure,	a	major	
adverse	event	with	deathly	consequences.		
In	 conclusion,	 in	 this	 large	 series	 of	 endoscopic	 stents	 for	 palliative	 intra-abdominal	
obstruction	we	showed	 that	 stent	placement	 in	 these	 situations	 is	 feasible	and	safe,	
independently	of	the	location	of	obstruction.	However,	carcinomatosis	not	only	limits	
the	clinical	success	of	this	procedure,	both	in	upper	and	lower	GI	tract	obstruction,	but	
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also	 increases	 the	 risk	 of	 serious	 complications.	 Therefore,	 in	 the	 scenario	 of	 intra-
abdominal	malignant	obstruction	in	patients	with	carcinomatosis,	especially	in	the	cases	
where	 carcinomatosis	 is	 the	 cause	 of	 obstruction,	 the	 decision	 of	 stent	 placement	
should	be	fully	scrutinized	and	may	not	always	be	an	adequate	option.	Just	because	we	
can	does	not	mean	we	should	do	it!	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
23	
References	
1.	Torre	LA,	Bray	F,	Siegel	RL,	Ferlay	J,	Lortet-Tieulent	J,	Jemal	A.	Global	cancer	statistics,	
2012.	CA:	A	Cancer	Journal	for	Clinicians	2015;	65	(2):87-108.	
2.	 Rothenberger	 DA.	 Palliative	 therapy	 of	 rectal	 cancer.	 Overview:	 epidemiology,	
indications,	goals,	extent,	and	nature	of	work-up.	Journal	of	gastrointestinal	surgery	:	
official	journal	of	the	Society	for	Surgery	of	the	Alimentary	Tract	2004;	8	(3):259-261.	
3.	Catalano	V,	Labianca	R,	Beretta	GD,	Gatta	G,	de	Braud	F,	Van	Cutsem	E.	Gastric	cancer.	
Crit	Rev	Oncol	Hematol	2009;	71	(2):127-164.	
4.	Kato	H,	Tsutsumi	K,	Okada	H.	Recent	advancements	in	stent	therapy	in	patients	with	
malignant	gastroduodenal	outlet	obstruction.	Ann	Transl	Med	2017;	5	(8):186.	
5.	Cetinkaya	E,	Dogrul	AB,	Tirnaksiz	MB.	Role	of	self	expandable	stents	in	management	
of	colorectal	cancers.	World	journal	of	gastrointestinal	oncology	2016;	8	(1):113-120.	
6.	Chandrasegaram	MD,	Eslick	GD,	Mansfield	CO,	Liem	H,	Richardson	M,	Ahmed	S,	et	al.	
Endoscopic	 stenting	 versus	 operative	 gastrojejunostomy	 for	malignant	 gastric	 outlet	
obstruction.	Surg	Endosc	2012;	26	(2):323-329.	
7.	Endo	S,	Takiguchi	S,	Miyazaki	Y,	Nishikawa	K,	Imamura	H,	Takachi	K,	et	al.	Efficacy	of	
endoscopic	gastroduodenal	stenting	for	gastric	outlet	obstruction	due	to	unresectable	
advanced	gastric	cancer:	a	prospective	multicenter	study.	Journal	of	surgical	oncology	
2014;	109	(3):208-212.	
8.	Varadarajulu	S,	Roy	A,	Lopes	T,	Drelichman	ER,	Kim	M.	Endoscopic	stenting	versus	
surgical	colostomy	for	the	management	of	malignant	colonic	obstruction:	comparison	
of	hospital	costs	and	clinical	outcomes.	Surg	Endosc	2011;	25	(7):2203-2209.	
		
24	
9.	 Mergener	 K,	 Kozarek	 RA.	 Stenting	 of	 the	 gastrointestinal	 tract.	 Dig	 Dis	 2002;	 20	
(2):173-181.	
10.	Mangiavillano	B,	Pagano	N,	Arena	M,	Miraglia	S,	Consolo	P,	Iabichino	G,	et	al.	Role	
of	 stenting	 in	 gastrointestinal	 benign	 and	 malignant	 diseases.	 World	 J	 Gastrointest	
Endosc	2015;	7	(5):460-480.	
11.	Masci	E,	Viale	E,	Mangiavillano	B,	Contin	G,	Lomazzi	A,	Buffoli	F,	et	al.	Enteral	self-
expandable	 metal	 stent	 for	 malignant	 luminal	 obstruction	 of	 the	 upper	 and	 lower	
gastrointestinal	 tract:	 a	prospective	multicentric	 study.	 J	 Clin	Gastroenterol	2008;	42	
(4):389-394.	
12.	Hong	SP,	Kim	TI.	Colorectal	stenting:	An	advanced	approach	to	malignant	colorectal	
obstruction.	World	J	Gastroenterol	2014;	20	(43):16020-16028.	
13.	Shin	YS,	Choi	CW,	Kang	DH,	Kim	HW,	Kim	SJ,	Cho	M,	et	al.	Factors	associated	with	
clinical	failure	of	self-expandable	metal	stent	for	malignant	gastroduodenal	obstruction.	
Scand	J	Gastroenterol	2016;	51	(1):103-110.	
14.	 Kim	 JH,	 Ku	 YS,	 Jeon	 TJ,	 Park	 JY,	 Chung	 JW,	 Kwon	 KA,	 et	 al.	 The	 efficacy	 of	 self-
expanding	metal	stents	for	malignant	colorectal	obstruction	by	noncolonic	malignancy	
with	peritoneal	carcinomatosis.	Diseases	of	the	colon	and	rectum	2013;	56	(11):1228-
1232.	
15.	Jeon	HH,	Park	CH,	Park	JC,	Shim	CN,	Kim	S,	Lee	HJ,	et	al.	Carcinomatosis	matters:	
clinical	 outcomes	 and	 prognostic	 factors	 for	 clinical	 success	 of	 stent	 placement	 in	
malignant	gastric	outlet	obstruction.	Surg	Endosc	2014;	28	(3):988-995.	
16.	 Yamao	K,	 Kitano	M,	 Kayahara	 T,	 Ishida	 E,	 Yamamoto	H,	Minaga	 K,	 et	 al.	 Factors	
predicting	through-the-scope	gastroduodenal	stenting	outcomes	in	patients	with	gastric	
		
25	
outlet	obstruction:	a	large	multicenter	retrospective	study	in	West	Japan.	Gastrointest	
Endosc	2016;	84	(5):757-763	e756.	
17.	Lee	JE,	Lee	K,	Hong	YS,	Kim	ER,	Lee	H,	Min	BH.	Impact	of	Carcinomatosis	on	Clinical	
Outcomes	after	Self-Expandable	Metallic	Stent	Placement	for	Malignant	Gastric	Outlet	
Obstruction.	PLoS	One	2015;	10	(10):e0140648.	
18.	Mendelsohn	RB,	Gerdes	H,	Markowitz	AJ,	DiMaio	CJ,	Schattner	MA.	Carcinomatosis	
is	not	a	contraindication	to	enteral	stenting	in	selected	patients	with	malignant	gastric	
outlet	obstruction.	Gastrointest	Endosc	2011;	73	(6):1135-1140.	
19.	 Faraz	 S,	 Salem	 SB,	 Schattner	 M,	 Mendelsohn	 R,	 Markowitz	 A,	 Ludwig	 E,	 et	 al.	
Predictors	of	clinical	outcome	of	colonic	stents	in	patients	with	malignant	large-bowel	
obstruction	due	to	extracolonic	malignancy.	Gastrointest	Endosc	2018.	
20.	Hori	Y,	Naitoh	I,	Hayashi	K,	Ban	T,	Natsume	M,	Okumura	F,	et	al.	Predictors	of	stent	
dysfunction	after	 self-expandable	metal	 stent	placement	 for	malignant	 gastric	outlet	
obstruction:	tumor	ingrowth	in	uncovered	stents	and	migration	of	covered	stents.	Surg	
Endosc	2017;	31	(10):4165-4173.	
21.	Tilney	HS,	Lovegrove	RE,	Purkayastha	S,	Sains	PS,	Weston-Petrides	GK,	Darzi	AW,	et	
al.	 Comparison	 of	 colonic	 stenting	 and	 open	 surgery	 for	 malignant	 large	 bowel	
obstruction.	Surg	Endosc	2007;	21	(2):225-233.	
22.	Kim	J,	Choi	IJ,	Kim	CG,	Lee	JY,	Cho	SJ,	Park	SR,	et	al.	Self-expandable	metallic	stent	
placement	 for	malignant	obstruction	 in	patients	with	 locally	recurrent	gastric	cancer.	
Surg	Endosc	2011;	25	(5):1505-1513.	
23.	Fernandez-Esparrach	G,	Bordas	JM,	Giraldez	MD,	Gines	A,	Pellise	M,	Sendino	O,	et	
al.	Severe	complications	limit	long-term	clinical	success	of	self-expanding	metal	stents	
		
26	
in	patients	with	obstructive	colorectal	cancer.	Am	J	Gastroenterol	2010;	105	(5):1087-
1093.	
24.	Karoui	M	CA,	Debaldo	C	et	al.	.	Stents	for	palliation	of	obstructive	metastatic	colon	
cancer:	 impact	 on	 management	 and	 chemotherapy	 administration.	 Arch	 Surg	
2007;142:619–23.	
25.	van	Hoo	JE	FP,	Marinelli	AW	et	al.	.	Early	closure	of	a	multicenter	randomized	clinical	
trial	 of	 endoscopic	 stenting	 vs.	 surgery	 for	 stage	 IV	 le	 -sided	 colorectal	 cancer.	 .	
Endoscopy	2008;40:184–91.	
26.	 Maire	 F,	 Hammel	 P,	 Ponsot	 P,	 Aubert	 A,	 O'Toole	 D,	 Hentic	 O,	 et	 al.	 Long-term	
outcome	 of	 biliary	 and	 duodenal	 stents	 in	 palliative	 treatment	 of	 patients	 with	
unresectable	adenocarcinoma	of	the	head	of	pancreas.	Am	J	Gastroenterol	2006;	101	
(4):735-742.	
27.	Oh	SY,	Edwards	A,	Mandelson	M,	Ross	A,	Irani	S,	Larsen	M,	et	al.	Survival	and	clinical	
outcome	 after	 endoscopic	 duodenal	 stent	 placement	 for	 malignant	 gastric	 outlet	
obstruction:	comparison	of	pancreatic	cancer	and	nonpancreatic	cancer.	Gastrointest	
Endosc	2015;	82	(3):460-468	e462.	
28.	Park	CH,	Park	JC,	Kim	EH,	Chung	H,	An	JY,	Kim	HI,	et	al.	Impact	of	carcinomatosis	and	
ascites	status	on	long-term	outcomes	of	palliative	treatment	for	patients	with	gastric	
outlet	 obstruction	 caused	 by	 unresectable	 gastric	 cancer:	 stent	 placement	 versus	
palliative	gastrojejunostomy.	Gastrointest	Endosc	2015;	81	(2):321-332.	
29.	Moon	SJ,	Kim	SW,	Lee	BI,	Lim	CH,	Kim	JS,	Soo	J,	et	al.	Palliative	stent	for	malignant	
colonic	obstruction	by	extracolonic	malignancy:	a	comparison	with	colorectal	cancer.	
Dig	Dis	Sci	2014;	59	(8):1891-1897.	
		
27	
30.	Ahn	HJ,	Kim	SW,	 Lee	SW,	 Lee	SW,	 Lim	CH,	Kim	 JS,	 et	 al.	 Long-term	outcomes	of	
palliation	 for	 unresectable	 colorectal	 cancer	 obstruction	 in	 patients	 with	 good	
performance	status:	endoscopic	stent	versus	surgery.	Surg	Endosc	2016;	30	(11):4765-
4775.	
31.	Cho	YK,	Kim	SW,	Nam	KW,	Chang	JH,	Park	JM,	Jeong	J-J,	et	al.	Clinical	outcomes	of	
self-expandable	metal	stents	in	palliation	of	malignant	anastomotic	strictures	caused	by	
recurrent	gastric	cancer.	World	Journal	of	Gastroenterology	2009;	15	(28):3523.	
32.	Park	JH,	Song	HY,	Kim	SH,	Shin	JH,	Kim	JH,	Kim	BS,	et	al.	Metallic	stent	placement	in	
patients	with	 recurrent	malignant	obstruction	 in	 the	 surgically	 altered	 stomach.	Ann	
Surg	Oncol	2014;	21	(6):2036-2043.	
33.	 Keswani	 RN,	 Azar	 RR,	 Edmundowicz	 SA,	 Zhang	 Q,	 Ammar	 T,	 Banerjee	 B,	 et	 al.	
Stenting	for	malignant	colonic	obstruction:	a	comparison	of	efficacy	and	complications	
in	colonic	versus	extracolonic	malignancy.	Gastrointestinal	Endoscopy	2009;	69	(3,	Part	
2):675-680.	
34.	 Rademacher	 C,	 Bechtler	M,	 Schneider	 S,	 Hartmann	 B,	 Striegel	 J,	 Jakobs	 R.	 Self-
expanding	 metal	 stents	 for	 the	 palliation	 of	 malignant	 gastric	 outlet	 obstruction	 in	
patients	with	peritoneal	carcinomatosis.	World	J	Gastroenterol	2016;	22	(43):9554-9561.	
35.	Koffler	KH,	Menkes	A,	Redmond	RA,	Whitehead	WE,	Pratley	RE,	Hurley	BF.	Strength	
training	accelerates	gastrointestinal	transit	in	middle-aged	and	older	men.	Medicine	and	
science	in	sports	and	exercise	1992;	24	(4):415-419.	
36.	Meisner	S,	Gonzalez-Huix	F,	Vandervoort	JG,	Goldberg	P,	Casellas	JA,	Roncero	O,	et	
al.	Self-expandable	metal	 stents	 for	 relieving	malignant	colorectal	obstruction:	 short-
		
28	
term	safety	and	efficacy	within	30	days	of	stent	procedure	in	447	patients.	Gastrointest	
Endosc	2011;	74	(4):876-884.	
37.	Mauro	MA,	 Koehler	 RE,	 Baron	 TH.	Advances	 in	 gastrointestinal	 intervention:	 the	
treatment	of	gastroduodenal	and	colorectal	obstructions	with	metallic	stents.	Radiology	
2000;	215	(3):659-669.	
38.	 Hori	 Y,	 Naitoh	 I,	 Hayashi	 K,	 Ban	 T,	 Natsume	M,	 Okumura	 F,	 et	 al.	 Predictors	 of	
outcomes	in	patients	undergoing	covered	and	uncovered	self-expandable	metal	stent	
placement	 for	malignant	gastric	outlet	obstruction:	a	multicenter	 study.	Gastrointest	
Endosc	2017;	85	(2):340-348	e341.	
39.	Zhang	Y,	Shi	 J,	Shi	B,	Song	CY,	Xie	WF,	Chen	YX.	Comparison	of	efficacy	between	
uncovered	 and	 covered	 self-expanding	 metallic	 stents	 in	 malignant	 large	 bowel	
obstruction:	 a	 systematic	 review	 and	 meta-analysis.	 Colorectal	 disease	 :	 the	 official	
journal	 of	 the	 Association	 of	 Coloproctology	 of	 Great	 Britain	 and	 Ireland	 2012;	 14	
(7):e367-374.	
40.	Sasaki	T,	 Isayama	H,	Nakai	Y,	Togawa	O,	Kogure	H,	Kawakubo	K,	et	al.	Predictive	
factors	 of	 solid	 food	 intake	 in	 patients	 with	 malignant	 gastric	 outlet	 obstruction	
receiving	self-expandable	metallic	stents	for	palliation.	Dig	Endosc	2012;	24	(4):226-230.	
	
	
	
	
	
		
29	
TABLES	
Table	1	Patient's	Baseline	Characteristics	
Baseline	Characteristics	 n	(%)	
No.	of	patients	 160	(100)	
Male	gender	 85	(53)	
Mean	age	(years)	±	SD	 64	±	14	
Mean	overall	survival	(days)	±	SD	 150	±	245	
ECOG	≥3	 52	(33)	
Obstruction	Location	 Upper	Gastrointestinal	Tract	 110	(69)	
Lower	Gastrointestinal	Tract	 50	(31)	
Tumor	diagnosis	 Gastric	 82	(52)	
Pancreatic	 20	(13)	
Colorectal	 44	(27)	
Gynaecological	 12	(8)	
Other	 2	(1)	
Comorbidities	 Smoking	 37	(23)	
Hypertension	 56	(35)	
Diabetes	mellitus	 23	(14)	
Cardiovascular	disease	 17	(11)	
Dyslipidaemia	 40	(25)	
Alcoholism	 18	(11)	
Carcinomatosis	 80	(50)	
Stent*	 Length	(mm)	 60	 55	(35)	
90	 81	(52)	
120	 21	(13)	
Type	 Uncovered	 155	(99)	
		
30	
	 Covered	 2	(1)	
Previous	treatment	 yes	 100	(63)	
	 CT	 54	(34)	
RT	 0	(0)	
Surgery	 7	(4)	
CT+RT	 7	(4)	
CT+Surgery	 25	(16)	
RT+Surgery	 1	(1)	
QT+RT+Surgery	 6	(4)	
	
	
	 	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
SD	–	Standard	Deviation;	ECOG	–	Eastern	Cooperative	Oncology;	CT	–	chemotherapy;	RT:	radiotherapy.	Group.		
*only	applicable	to	patient’s	whose	stent	was	technically	successful	(157).		
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Table	2.	Univariate	analysis	of	factors	predicting	early	and	late	clinical	outcomes.	
Factors	
Early	Clinical	Success	(157	
patients)	
Late	Clinical	Success	
(157	patients)	
Late	Clinical	Benefit	(157	
patients)	
n(%)	 p	
value	
O.R.(95%CI)	 N(%)	 p	
value	
O.R.	
(95%	
CI)	
n(%)	 p		
value	
O.R.	
(95%	CI)	
Age	(≥65years)	
60	
(78)	
0.143	 0.8	(0.5-1.1)	
45	
(58)	
0.170	
0.8	
(0.6-
1.1)	
35	
(46)	
0.490	
0.9	(0.7-
1.2)	
Male	Gender	
64	
(76)	
0.281	 0.8	(0.6-1.2)	
45	
(54)	
0.849	
1.0	
(0.7-
1.3)	
33	
(39)	
0.357	
1.2	(0.9-
1.6)	
Previous	Treatment	
65	
(67)	
0.045	 1.3	(1.0-1.7)	
50	
((52)	
0.674	
1.1	
(0.9-
1.3)	
42	
(43)	
0.841	
1.0	(0.8-
1.0)	
Intervenient		 Endoscopist	1	
89	
(72)	
0.892	
1.0	(0.8-1.2)	
63	
(51)	
0.691	
1.0	
(0.9-
1.2)	
52	
(42)	
0.848	
1.0	
(0.9-.1.2)	
Endoscopist	2	
25	
(74)	
0.9	(0.5-1.9)	
19	
(56)	
0.9	
(0.5-
1.6)	
15	
(44)	
	
0.9	(0.5-
1.7)	
Obstruction	
Location	
Upper	
Gastrointestinal	
Tract	
75	
(69)	
0.107	 1.2	(0.9-1.5)	
54	
(50)	
0.209	
1.1	
(0.9-
1.4)	
41	
(38)	
0.053	
1.2	(0.9-
1.6)	
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Lower	
Gastrointestinal	
Tract	
39	
(81)	
0.6	(0.3-1.2)	
29	
(60)	
0.7	
(0.5-
1.2)	
26	
(57)	
0.6	(0.4-
1)	
Stent	Length	 60	
42	
(75)	
0.752	
0.9	(0.5-1.5)	
26	
(46)	
0.321	
1.3	
(0.8-
2.0)	
22	
(39)	
0.650	
1.2	(0.7-
1.8)	
90	
56	
(70)	
1.1	(0.8-1.6)	
47	
(59)	
0.8	
(0.6-
1.1)	
37	
(46)	
0.9	(0.6-
1.2)	
120	
16	
(70)	
0.8	(0.3-2.1)		
10	
(48)	
1.2	
(0.6-
2.7)	
8	
(38)	
1.2	(0.5-
2.8)	
ECOG≥3	
34	
(65)	
0.153	 1.4	(0.9-2.2)	
24	
(46)	
0.236	
1.3	
(0.8-
2.0)	
20	
(39)	
0.453	
1.2	(0.8-
1.9)	
Carcinomatosis		
45	
(58)	
<0.001	 1.9	(1.4-2.5)	
31	
(40)	
0.002	
1.7	
(1.2-
2.3)	
22	
(29)	
<0.001	
1.9	(1.3-
2.7)	
	
	
	
	
O.R.	-	Odds	ratio;	95%	CI	–	95%	Confidence	interval.	
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Table	3	Subanalysis	of	factors	predicting	early	and	late	clinical	success	in	the	Upper	
and	Lower	GI	tracts		
Upper	Gastrointestinal	Tract	(109	patients)	
Factors	
Early	Clinical	Success	 Late	Clinical	Success	 Late	Clinical	Benefit	
n(%)		 pvalue	 O.R.	(95%	
CI)	
n(%)	 p	
value	
O.R.	(95%CI)	 n(%)	 p	value	 O.R.	(95%	
CI)	
Age	(≥65years)	 13	(26)	 0.281	 0.8	(0.5-1.3)	 27(54)	 0.391	 0.8	(0.6-1.3)	 19	(38)	 P=0.939	 1.0	(0.6-1.5)	
Male	Gender	 45	(74)	 0.207	 0.8	(0.5-1.2)	 31	(51)	 0.763	 1.0	(0.7-1.3)	 21	(34)	 P=0.439	 1.1	(0.8-1.6)	
Previous	Treatment	 40	(62)	 0.046	 1.4	(1.0-1.8)	 31	(48)	 0.639	 1.1	(0.8-1.5)	 25	(39)	 P=0.824	 1.1	(0.7-1.7)	
Intervenient		 Endoscopist	
1	
54	(62)	
0.625	
1.1	(0.8-1.3)	 38	(48)	
0.479	
1.1	(0.9-1.4)	 29	(36)	
P=0.625	
1.1	(0.8-1.3)	
Endoscopist	
2	
21	(72)	 0.8	(0.4-1.7)	 16	(55)	 0.8	(0.4-1.5)	 12	(41)	 0.9	(0.6-1.2)	
Stent	
Length	
60	 29	(73)	
0.553	
0.8	(0.6-1.3)	 17	(43)	
0.534	
1.3	(0.8-2.2)	 13	(33)	
P=0.692	
1.3	(0.7-2.1)	
90	 36	(64)	 1.2	(0.8-1.8)	 30	(54)	 0.9	(0.6-1.2)	 13	(33)	 0.9	(0.6-1.2)	
120	 10	(77)	 0.7	(0.2-2.3)	 7	(54)	 0.8	(0.3-2.3)	 5	(14)	 1.0	(0.3-2.8)	
ECOG≥3	 26	(70)	 0.813	 0.9	(0.5-1.7)	 18	(49)	 0.894	 1.0	(0.6-1.8)	 14	(38)	 P=0.972	 1.0	(0.6-1.7)	
Carcinomatosis	 34	(57)	 0.002	 1.7	(1.2-2.3)	 24(40)	 0.027	 1.5	(1.0-2.1)	 16	(28)	 P=0.009	 1.7	(1.1-2.5)	
Lower	Gastrointestinal	Tract	(48	patients)	
Factors	
Early	Clinical	Success	 Late	Clinical	Success	 Late	Clinical	Benefit	
n(%)	 pvalue	 O.R.	(95%	
CI)	
n(%)	 p	
value	
O.R.	(95%CI)	 n(%)	 p	value	 O.R.	(95%	CI)	
Age	(≥65years)	 23	
(85)	
0.428	 0.8	(0.3-1.6)	 18	(67)	 0.315	 0.8	(0.4-1.3)	 16	(62)	 0.422	 0.8	(0.5-1.4)	
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Male	Gender	 19	
(83)	
0.817	 0.9	(0.4-2.0)	 14	(61)	 0.951	 1.0	(0.5-1.8)	 12	(46)	 0.791	 0.9	(0.5-1.6)	
Previous	Treatment	 25	
(78)	
0.433	 1.2	(0.8-1.8)	 19	(59)	 0.835	 1.0	(0.7-1.8)	 17	(65)	 0.838	 1.0	(0.7-1.6)	
Intervenient		 Endoscopist	1	 35	
(81)	 0.940	
1.0	(0.8-1.3)	 26(61)	
0.984	
1.0	(0.8-1.2)	 23	(54)	
0.782	
1.0	(0.8-1.3)	
Endoscopist	2	 4	(80)	 1.1	(0.1-8.6)	 3(60)	 1.0	(0.2-5.5)	 3	(60)	 0.8	(1.4-4.3)	
Stent	
Length	
60	 13	
(81)	
0.872	
1	(0.4-2.8)	 9	(56)	
0.227	
1.2	(0.5-2.6)	 9	(56)	
0.580	
0.9	(0.4-2.1)	
90	 20	
(83)	
0.9	(0.4-1.9)	 17	(71)	 0.6	(0.3-1.2)	 14	(58)	 0.8	(0.5-1.5)	
120	 6	(75)	 1.4	(0.3-6.0)	 13	(38)	 2.6	(0.7-9.4)	 3	(38)	 2.0	(0.6-7.3)	
ECOG≥3	 8	(53)	 0.001	 3.8	(1.9-7.7)	 6(40)	 0.051	 2.3	(0.9-5.4)	 6	(40)	 0.184	 1.8	(0.8-4.2)	
Carcinomatosis	 11	
(23)	
0.03	 2.4	(1.2-4.7)	 7(41)	 0.044	 2.2	(1.0-4.7)	 6	(35)	 0.051	 2.2	(1.0-4.9)	
O.R.	-	Odds	ratio;	95%	CI	–	95%	Confidence	interval.	
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Table	4.	Univariate	analysis	of	cause	of	obstruction’s	association	with	clinical	success	
within	the	upper	and	lower	GI	tracts.	
Upper	Gastrointestinal	Tract	(109	patients)	
Cause	of	
obstruction	
Early	Clinical	Success	 Late	Clinical	Success	 Late	Clinical	Benefit	
n(%)	 p	
value	
O.R.	
(95%CI)	
n(%)	 p	
value	
O.R.	
(95%CI)	
n(%)	 p	
value	
O.R.	(95%CI)	
	
Gastric	Cancer	
(n=62)	
47(76)	 0.070	 0.7	
(0.5-
1.1)	
34(55)	 0.204	
	
0.8	(0.6-1.1)	 26	
(42)	
0.880	 0.8	(0.6-1.2)	
Recurrence	of	
Gastric	Cancer	in	
Anastomosis	Site	
(n=7)	
5(71)	 0.877	 0.9	
(0.2-
4.3)	
3	(43)	 0.715	
	
1.3	(0.3-5.6)	 3(43)	 0.767	 0.8	(0.2-3.4)	
Pancreatic	Cancer	
(n=18)	
15(83)	 0.145	 0.5	
(0.2-
1.2)	
12	
(67)	
0.112	
	
0.5	(0.2-1.2)	 9	
(50)	
0.235	 0.6	(0.2-3.4)	
Carcinomatosis	
(n=16)	
5(31)	 <0.001	 4.9	
(1.8-
12.9)	
3(19)	 0.008	
	
4.3	(1.3-
14.1)	
2(13)	 0.025	 4.2	(1.0-17.6)	
Hepathic	
Methastasis	(n=2)	
2(100)	 1	 -	 2	
(100)	
0.243	
	
-	 1	
(50)	
1	 0.6	(0.4-9.4)	
Adenopathies	
(n=4)	
1(25)	 0.089	 6.6	
(0.7-
61.3)	
0(0)	 0.118	 -	 0	 0.295	 -	
Lower	Gastrointestinal	Tract		(48	patients)	
Early	Clinical	Success	 Late	Clinical	Success	 Late	Clinical	Benefit	
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Cause	of	
obstruction	
n(%)	 p	
value	
O.R.	
95%C.I.	
n(%)	 p	
value	
O.R.	
(95%C.I.)	
n(%)	 p	
value	
O.R.	(95%CI)	
	
Carcinomatosis		
(n=9)	
5	(56)	 0.028	 3.5	
(1.2-
10.4)	
	
	
2(22)	 0.009	 5.3	(1.2-
23.0)	
2	
(22)	
0.033	 4.1	(1.0-17.9)	
Gynecological	
Cancer(n=1)	
1	
(100)	
1	 -	 1(100)	 1	 -	 1	
(100)	
0.458	 	
Colorectal	Cancer	
(n=38)	
33	
(85)	
0.053	 0.7	
(0.3-
1.2)	
26(68)	 0.027	 0.7	(0.5-1.0)	 24	
(65)	
0.006	 0.7	(0.5-1.0)	
O.R.	-	Odds	ratio;	95%	CI	–	95%	Confidence	interval.	
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Table	5.	Multivariate	analysis	of	factors	associated	with	early	clinical	failure,	late	clinical	
failure	and	absence	of	late	clinical	benefit	within	the	upper	and	lower	gastrointestinal	
tract	
Upper	Gastrointestinal	Tract		(109	patients)	
Factors	
Early	Clinical	Failure	 Late	Clinical	Failure		 Absence	of	Late	Clinical	Benefit	
O.R.	
(95%CI)	
P	value	 O.R.	(95%CI)	 P	value	 O.R.	(95%CI)	 P	value	
Age	(≥65years)	 0.7	(0.3-
1.9)	
0.542	 0.7	(0.3-1.6)	 0.379	 1.0	
(0.4-2.3)	
0.943	
Male	Gender	 2.0	(0.8-
5.0)	
0.151	 1.1(0.5-2.6)	 0.771	 0.7	
(0.3-1.7)	
0.436	
ECOG≥3	 0.9	(0.3-
2.3)	
0.777	 1.1(0.5-2.8)	 0.762	 1.1	
(0.5-2.8)	
0.785	
Carcinomatosis	 	
	 No	carcinomatosis	 1	 	 1	 	 1	 	
	 Carcinomatosis	but	not	
as	the	cause	of	
obstruction	
2.8	(1.0-
7.9)	
0.051	 1.767	
(0.742-
4.208)	
0.199	 2.2	(0.9-5.5)	 0.076	
	 Carcinomatosis	as	the	
cause	of	obstruction	
9.7	(2.5-
38.4)	
0.001	 7.6	(1.8-
31.9)	
0.006	 9.2	(1.8-47.0)	 0.008	
Previous	treatment	 1.5	(0.5-
4.2)	
0.606	 0.8(0.3-1.8)	 0.525	 0.6	(0.3-1.5)	
	
0.295	
Lower	Gastrointestinal	Tract		(48	patients)	
Factors	 Early	Clinical	Failure	 Late	Clinical	Failure	 Absence	of	Late	Clinical	Benefit	
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O.R.	
(95%CI)	
P	value	 O.R.	(95%CI)	 P	value	 O.R.	(95%CI)	 P	value	
Age	(≥65years)	 1.0	(0.1-
6.7)	
0.966	 0.426	(0.1-
1.7)	
0.232	 0.5	(0.1-1.9)	 0.317	
Male	Gender	 0.6	(0.1-
4.8)	
0.621	 0.7	(0.1-3.0)	 0.587	 0.6	(0.3-2.5)	 0.494	
ECOG≥3	 29.8	(1.9-
464.9)	
0.002	 4.3	(0.8-
23.1)	
0.092	 2.4	(0.5-11.0)	 0.266	
Carcinomatosis	 	
	 No	carcinomatosis	 1	 	 1	 	 1	 	
Carcinomatosis	but	not	
as	the	cause	of	
obstruction	
3.6	(0.3-
38.7)	
0.292	 1.2	(0.2-6.9)	 0.858	 1.5	
(0.3-7.9)	
0.635	
Carcinomatosis	as	the	
cause	of	obstruction	
8.2	(0.8-
89.0)	
0.084	 14.4	(1.7-
119.6)	
0.013	 8.3	
(1.2-57.6)	
0.035	
Previous	treatment	 0.2	(0.01-
3.6)	
0.261	 0.4(0.7-1.9)	 0.239	 0.6	
(0.1-2.6)	
0.475	
O.R.	-	Odds	ratio;	95%	CI	–	95%	Confidence	interval.	
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Table	6.	Stent	dysfunction	and	perforation.		
	
	
	
	
	
	
	
	
	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stent	
dysfunction	
Total	 Patients	with	
carcinomatosis	
Patients	without	
carcinomatosis	
	
n(%)	 n(%)	
	
n(%)	 p	value	
Migration	 7(4)	
	
2(3)	
	
5(6)	
	
P=0.268	
Restenosis	 14(9)	
	
8(10)	
	
6(8)	
	
P=0.525	
Adverse	Events	 	
Perforation	
4(3)	
	
4(5)	
	
0(0)	
	
P=0.039	
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FIGURE	LEGEND	
Figure	 1.	 Kaplain-Meier	 plot	 for	 overall	 survival	 according	 to	 the	 presence	 of	
carcinomatosis.	Cumulative	overall	survival	was	lower	in	patients	with	carcinomatosis	
compared	to	those	without	carcinomatosis	 (122	days,	95%	CI	83-161	vs.	243,	95%	CI	
154-333;	p=0.02)		
Figure	2.	 	Kaplain-Meier	plot	 for	symptom-free	survival	according	 to	 the	presence	of	
carcinomatosis.	 Cumulative	 symptom-free	 survival	 was	 lower	 in	 patients	 with	
carcinomatosis	compared	to	those	without	carcinomatosis	(66	days,	95%	CI	32-100	vs.	
183,	95%	CI	83-282;	p=0.002)		
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